There is continuing debate about the relative efficacy of low (< 100 mg per day), medium (300 to 325 mg per day), and high (> 900 mg per day) doses of aspirin in patients after a transient ischaemic attack or non-disabling stroke. The purpose of this study was 
aspirin a day for the secondary prevention of stroke.' In an inquiry among 44 leading neurologists 42 (95%) preferred a dose of 325 mg or less; nine (20%) prescribed 100 mg or less for this indication.2 Nevertheless the efficacy of low or medium dose aspirin (s< 325 mg per day) has been questioned. 3 This has again fuelled a debate on the relative efficacy of low or medium v high doses of aspirin. 4 In the second cycle of the Antiplatelet Trialists' Collaboration 18 randomised trials in patients with cerebral ischaemia were included in the analyses and the raw tabular data on single trials were provided in an appendix. 5 We performed a minimeta-analysis with these data to try and resolve the controversy.
Methods
The present analysis is restricted to the efficacy of various doses of aspirin only, without interference from other antiplatelet drugs. Therefore we selected those trials in which aspirin only was compared with control treatment. The composite outcome of vascular death, stroke, or myocardial infarction was chosen for the analysis because we agree with the Antiplatelet Trialists' Collaboration that this measure of outcome is the most relevant from the patient's point of view and also provides the largest number of events for analysis which are likely to be influenced by antiplatelet treatment. The relative risk and corresponding relative risk reduction ((1 -relative risk) x 100%) were used as the effect measure rather than the odds ratio and relative odds Cumulative RR and 95% Cl Figure 2 shows the results of the cumulative meta-analysis, in chronological order, regardless of the dose of aspirin. those of other antiplatelet agents, and only for patients after cerebral ischaemia. However, discussants of low and medium dose aspirin after cerebral ischaemia base their arguments on even more incomplete reviews of trials (some including other antiplatelet treatments).3 To bring the dispute on the dose of aspirin into focus we reanalysed all trials with aspirin only in patients after cerebral ischaemia. Moreover, it is a matter of judgement whether to analyse the data of all atherosclerotic diseases combined or in separate disease categories. A second objection could be that the 10 trials are too different to be combined. Table 1 , however, shows that major baseline risk factors are no more different between trials than within large trials. For example, in the Dutch TIA trial the annual risk of a vascular event in the average female patient with a transient ischaemic attack who was younger than 65 years and had no history of myocardial infarction was 1-3%, against 11-9% in a man with a non-disabling stroke who was 65 years or older and who did have a history of myocardial infarction. 21 Our minimeta-analysis shows similar efficacy of low, medium, and high doses of aspirin, although for all regimens the 95% CI of the risk reduction ranges from about 25% to about 0%. Theoretically a true difference might still be hidden between these extremes.
But a similar efficacy between medium and high doses is corroborated by the data of the UK-TIA trial which showed hardly any difference between 300 and 1200 mg daily, the point estimate of the relative risk being almost unity.'9 The direct comparison between 30 (low dose) and 283 mg (medium dose) in the Dutch TIA trial again showed no major differences. 22 Hence, we conclude that the efficacy in secondary prevention after cerebral ischaemia is similar for any dose of aspirin between 30 and 1500 mg a day.
In a recent review Barnett et al also included a minimeta-analysis of aspirin trials in patients after cerebral ischaemia.2' Although non-fatal myocardial infarction was not included in their analysis a similar, low efficacy of aspirin was found with hardly any differences between different doses. Their recommendation to start with an initial dose of no less than 650 mg daily, however, is at variance with the conservative principle of medicine "primum non nocere". Given equal efficacy of low, medium, and high dose aspirin, the harmful side effects at high doses tilt the balance towards low doses (table 2) .19 22 The cumulative meta-analysis shows the historical development of the magnitude of relative risk reduction which was generally attributed to treatment with aspirin. At the end of the 1970s the perceived relative risk reduction was about 30%, but the confidence interval was wide. In the mid-1980s, after the publication of AICLA and the Danish cooperative study, the cumulative evidence shifted to a relative risk reduction of just over 20%. After the publication of SALT in 1991 the overall relative risk reduction arrived at 13% with a 95% CI of 4 to 21%.
Because the point estimate of the risk reduction with aspirin is a modest 13%, the main message of this minimeta-analysis is that more potent approaches for secondary prevention after cerebral ischaemia are needed. For this reason we have launched SPIRIT (Stroke Prevention In Reversible Ischemia Trial) which compares anticoagulation and aspirin.24
We are grateful to professor CP Warlow and professor R Peto for criticisms on earlier drafts of this paper; we think it only fair to add that professor Peto considers that only the collective evidence (all arterial disease and all antiplatelet agents) should be reviewed, partial reviews being potentially misleading. We thank Dr FR Rosendaal for his remarks on this partial metaanalysis.
